XML 41 R30.htm IDEA: XBRL DOCUMENT
v3.21.2

Collaboration and Licensing Revenue (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summarized Collaboration and Licensing Revenues | The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2021 and 2020.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
ZIOPHARM Oncology, Inc. | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 100 |
Oragenics, Inc. | — |  |  | 2,823 |  |  | — |  |  | 3,053 |
Castle Creek Biosciences, Inc. | 18 |  |  | 2,394 |  |  | 371 |  |  | 16,967 |
Other | 4 |  |  | 6 |  |  | 18 |  |  | 139 |
Total (1) | $ | 22 |  |  | $ | 5,223 |  |  | $ | 389 |  |  | $ | 20,259 |
(1)Collaboration and licensing revenues include the recognition of $22 and $5,213 for the three months ended September 30, 2021 and 2020, respectively, and $380 and $19,654 for the nine months ended September 30, 2021 and 2020, respectively, associated with upfront and milestone payments which were previously deferred.
Summary of Deferred Revenue | Deferred revenue consisted of the following:
| September 30, 2021 |  | December 31, 2020
Collaboration and licensing agreements | $ | 23,040 |  |  | $ | 23,420 |
Prepaid product and service revenues | 3,493 |  |  | 2,126 |
Other | 183 |  |  | 277 |
Total | $ | 26,716 |  |  | $ | 25,823 |
Current portion of deferred revenue | $ | 3,693 |  |  | $ | 2,800 |
Long-term portion of deferred revenue | 23,023 |  |  | 23,023 |
Total | $ | 26,716 |  |  | $ | 25,823 |
Summary of Deferred Revenue by Collaborator | The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of September 30, 2021 and December 31, 2020, as well as the estimated remaining performance period as of September 30, 2021.
| Average Remaining Performance Period (Years) |  | September 30, 2021 |  | December 31, 2020
Intrexon Energy Partners, LLC | 2.5 |  | $ | 8,362 |  |  | $ | 8,362 |
Intrexon Energy Partners II, LLC | 3.2 |  | 12,843 |  |  | 12,843 |
Castle Creek Biosciences, Inc. | 0.3 |  | 17 |  |  | 379 |
Other | 3.1 |  | 1,818 |  |  | 1,836 |
Total |  |  | $ | 23,040 |  |  | $ | 23,420 |

X
- Definition Tabular disclosure of summarized revenues recognized for each significant collaboration and licensing agreement and aggregated nonsignificant collaborations and licensing agreements. + References No definition available. + Details
Name: | pgen_CollaborationandLicensingRevenueTableTextBlock
Namespace Prefix: | pgen_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration